StockData

Adaptive Biotechnologies vs ImmunityBio

ADPT and IBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADPT and IBRX compare

ImmunityBio is the larger company, worth 1.4 times as much as Adaptive Biotechnologies ($6.4B against $4.6B).

ImmunityBio grew revenue faster over the last twelve months (121% versus 17.9% for Adaptive Biotechnologies).

Adaptive Biotechnologies keeps more of each dollar of sales as profit, with a net margin of −23.7% compared with −608% at ImmunityBio.

Adaptive Biotechnologies scores higher on the StockData Score (12 against 8 for ImmunityBio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADPTIBRX
Size and price
Market cap$4.6B$6.4B
Share price$29.04$6.02
Change, 1 year100%192%
Change, 5 years6.2%−6.4%
Beta (5Y)1.791.53
Employees624691
StockData Score
Total score12 (better)8
Valuation score00
Growth score4 (better)2
Performance score3 (better)1
Health score55
Dividend score00
Valuation
P/S15.6× (better)34.9×
P/B26.3×–
FCF yield−0.19% (better)−4.7%
Fair value$6.88–
Margin of safety−322%–
Growth
Revenue growth (TTM)17.9%121% (better)
Revenue growth, 5Y average23.0%185% (better)
Profitability
Gross margin74.2%98.8% (better)
Operating margin−16.2% (better)−150%
Net margin−23.7% (better)−608%
FCF margin−3.0% (better)−163%
Return on equity−37.1%–
Return on invested capital−9982%–
Financial health
Debt / equity0.00–
Interest coverage−5.3×–
Current ratio3.974.27 (better)
Altman Z-score3.38 (better)−9.34
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.6%19.1%
Held by insiders22.7%75.2%
Insider net buying, 12 months−$117M−$9.5M (better)
Superinvestors holding1–
Short interest, % of float9.3%48.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.